<DOC>
	<DOCNO>NCT02924155</DOCNO>
	<brief_summary>This study randomize , double-blind , placebo-controlled , single day/multiple day dosing , Phase I clinical trial investigate systemic exposure , safety local tolerability SJP002 ophthalmic solution healthy Korean male volunteer .</brief_summary>
	<brief_title>Clinical Study Investigate Systemic Exposure , Safety , Local Tolerability SJP002 Ophthalmic Solution Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Healthy Korean male 2050 year old Present condition history clinically significant disease History hypersensitivity , include drug allergy Present condition history follow disease ; History Keratitis , Uveitis , Retinitis , Dry eye syndrome , Corrective sight scale 20/40 ( 0.5 ) , Present adverse reaction wear contact lens plan wear contact lens , History ophthalmic surgery . Drug abuse within 60 day , positive reaction Drug test Urine Taken ETC herbal supplement within 14 day OTC vitamin supplement within 7 day Participation administration IP another clinical trial within 90 day Donation whole blood within 60 day blood component within 30 day , receipt blood transfusion within 30 day Consumption 21 unit alcohol/week inability abstain drink study period Smoking within 90 day Plan pregnant , use appropriate method contraception</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>